Impact of coronary artery disease on clinical outcomes after TAVR: Insights from the BRAVO-3 randomized trial.
Humans
Heparin
/ adverse effects
Coronary Artery Disease
/ complications
Transcatheter Aortic Valve Replacement
/ adverse effects
Antithrombins
/ adverse effects
Treatment Outcome
Hirudins
/ adverse effects
Hemorrhage
/ chemically induced
Peptide Fragments
/ adverse effects
Recombinant Proteins
/ adverse effects
TAVR
aortic stenosis
coronary artery disease
outcomes
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
15
02
2023
received:
18
11
2022
accepted:
08
03
2023
medline:
11
5
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
To determine the prognostic impact of coronary artery disease (CAD) in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR). CAD is a common comorbidity among patients undergoing TAVR and studies provide conflicting data on its prognostic impact. The Bivalirudin on Aortic Valve Intervention Outcomes-3 (BRAVO-3) randomized trial compared the use of bivalirudin versus UFH in 802 high-surgical risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence or absence of history of CAD as well as periprocedural anticoagulation. The coprimary endpoints were net adverse cardiac events (NACE; a composite of all-cause mortality, myocardial infarction, stroke, or major bleeding) and major Bleeding Academic Research Consortium (BARC) bleeding ≥3b at 30 days postprocedure. Among 801 patients, 437 (54.6%) had history of CAD of whom 223 (51.0%) received bivalirudin. There were no significant differences in NACE (adjusted odds ratio [OR]: 1.04; 95% confidence interval [CI]: 0.69-1.58) or BARC ≥ 3b bleeding (adjusted OR: 0.84; 95% CI: 0.51-1.39) in patients with vs without CAD at 30 days. Among CAD patients, periprocedural use of bivalirudin was associated with similar NACE (OR: 0.80; 95% CI: 0.47-1.35) and BARC ≥ 3b bleeding (OR: 0.64; 95% CI: 0.33-1.25) compared with UFH, irrespective of history of CAD (p-interaction = 0.959 for NACE; p-interaction = 0.479 for major bleeding). CAD was not associated with a higher short-term risk of NACE or major bleeding after TAVR. Periprocedural anticoagulation with bivalirudin did not show any advantage over UFH in patients with and without CAD.
Sections du résumé
OBJECTIVE
To determine the prognostic impact of coronary artery disease (CAD) in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).
BACKGROUND
CAD is a common comorbidity among patients undergoing TAVR and studies provide conflicting data on its prognostic impact.
METHODS
The Bivalirudin on Aortic Valve Intervention Outcomes-3 (BRAVO-3) randomized trial compared the use of bivalirudin versus UFH in 802 high-surgical risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence or absence of history of CAD as well as periprocedural anticoagulation. The coprimary endpoints were net adverse cardiac events (NACE; a composite of all-cause mortality, myocardial infarction, stroke, or major bleeding) and major Bleeding Academic Research Consortium (BARC) bleeding ≥3b at 30 days postprocedure.
RESULTS
Among 801 patients, 437 (54.6%) had history of CAD of whom 223 (51.0%) received bivalirudin. There were no significant differences in NACE (adjusted odds ratio [OR]: 1.04; 95% confidence interval [CI]: 0.69-1.58) or BARC ≥ 3b bleeding (adjusted OR: 0.84; 95% CI: 0.51-1.39) in patients with vs without CAD at 30 days. Among CAD patients, periprocedural use of bivalirudin was associated with similar NACE (OR: 0.80; 95% CI: 0.47-1.35) and BARC ≥ 3b bleeding (OR: 0.64; 95% CI: 0.33-1.25) compared with UFH, irrespective of history of CAD (p-interaction = 0.959 for NACE; p-interaction = 0.479 for major bleeding).
CONCLUSION
CAD was not associated with a higher short-term risk of NACE or major bleeding after TAVR. Periprocedural anticoagulation with bivalirudin did not show any advantage over UFH in patients with and without CAD.
Substances chimiques
Heparin
9005-49-6
Antithrombins
0
tetrachloroisophthalonitrile
J718M71A7A
Hirudins
0
Peptide Fragments
0
Recombinant Proteins
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1143Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Paradis JM, Fried J, Nazif T, et al. Aortic stenosis and coronary artery disease: what do we know? What don't we know? A comprehensive review of the literature with proposed treatment algorithms. Eur Heart J. 2014;35(31):2069-2082.
Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373(9667):956-966.
Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142-147.
Aranki SF, Rizzo RJ, Couper GS, et al. Aortic valve replacement in the elderly. Effect of gender and coronary artery disease on operative mortality. Circulation. 1993;88(5 pt 2):17-23.
Beach JM, Mihaljevic T, Svensson LG, et al. Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. JACC. 2013;61(8):837-848.
Tjang YS, van Hees Y, Körfer R, Grobbee DE, van der Heijden GJMG. Predictors of mortality after aortic valve replacement. Eur J Cardiothorac Surg. 2007;32(3):469-474.
Craver JM, Weintraub WS, Jones EL, Guyton RA, Hatcher CR Jr.Predictors of mortality, complications, and length of stay in aortic valve replacement for aortic stenosis. Circulation. 1988;78(3 pt 2):85-90.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. JACC. 2014;63(22):e57-e185.
Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-2496.
Hioki H, Watanabe Y, Kozuma K, et al. Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding. Heart. 2017;103(5):361-367.
Genereux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol. 2012;59(25):2317-2326.
Genereux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63(11):1100-1109.
Holmes DR Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. JACC. 2012;59(13):1200-1254.
Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
Dangas GD, Lefèvre T, Kupatt C, et al. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement. JACC. 2015;66(25):2860-2868.
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736-2747.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation. JACC. 2012;60(15):1438-1454.
Rapp AH, Hillis LD, Lange RA, Cigarroa JE. Prevalence of coronary artery disease in patients with aortic stenosis with and without angina pectoris. Am J Cardiol. 2001;87(10):1216-1217.
Adler Y, Vaturi M, Herz I, et al. Nonobstructive aortic valve calcification: a window to significant coronary artery disease. Atherosclerosis. 2002;161(1):193-197.
Walther T, Hamm CW, Schuler G, et al. Perioperative results and complications in 15,964 transcatheter aortic valve replacements. J Am Coll Cardiol. 2015;65(20):2173-2180.
Cao D, Chiarito M, Pagnotta P, Reimers B, Stefanini GG. Coronary revascularisation in transcatheter aortic valve implantation candidates: why, who, when? Interv Cardiol. 2018;13(2):69-76.
Kotronias RA, Kwok CS, George S, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(6):e005960.
D'Ascenzo F, Verardi R, Visconti M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. EuroIntervention. 2018;14(11):e1169-e1177.
Ussia GP, Barbanti M, Colombo A, et al. Impact of coronary artery disease in elderly patients undergoing transcatheter aortic valve implantation: insight from the Italian CoreValve Registry. Int J Cardiol. 2013;167(3):943-950.
D'Ascenzo F, Conrotto F, Giordana F, et al. Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a meta-analysis of adjusted observational results. Int J Cardiol. 2013;168(3):2528-2532.
Masson JB, Lee M, Boone RH, et al. Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2010;76(2):165-173.
Paradis JM, White JM, Généreux P, et al. Impact of coronary artery disease severity assessed with the SYNTAX score on outcomes following transcatheter aortic valve replacement. J Am Heart Assoc. 2017;6(2):e005070.
Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(14):1428-1435.
Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J. 2014;35(37):2530-2540.
Guedeney P, Tchétché D, Petronio AS, et al. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: from the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019;93(6):1124-1131.
Sankaramangalam K, Banerjee K, Kandregula K, et al. Impact of coronary artery disease on 30-day and 1-year mortality in patients undergoing transcatheter aortic valve replacement: a meta-analysis. J Am Heart Assoc. 2017;6(10):e006092.
Meneguz-Moreno RA, Ramos AI, Siqueira D, et al. Prognostic value of renal function in patients with aortic stenosis treated with transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2017;89(3):452-459.
Barbash IM, Ben-Dor I, Dvir D, et al. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. Am Heart J. 2012;163(6):1031-1036.
Arsalan M, Squiers JJ, Farkas R, et al. Prognostic usefulness of acute kidney injury after transcatheter aortic valve replacement. Am J Cardiol. 2016;117(8):1327-1331.
Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J. 2010;31(7):865-874.
Elhmidi Y, Bleiziffer S, Deutsch MA, et al. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis. 2014;107(2):133-139.
Cheungpasitporn W, Thongprayoon C, Kashani K. Transcatheter aortic valve replacement: a kidney's perspective. J Renal Inj Prev. 2016;5(1):1-7.
Nuis RJM, Van Mieghem NM, Tzikas A, et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2011;77(6):881-889.
Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry. Circ Cardiovasc Interv. 2017;10(10):e005456.
Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359(7):688-696.
Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863.
Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203-2216.
Patterson T, Clayton T, Dodd M, et al. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION). J Am Coll Cardiol Intv. 2021;14(18):1965-1974.
Mylotte D, Wijns W. Anatomical or functional assessment of coronary artery disease in aortic stenosis: haven't we been down this road before? J Am Heart Assoc. 2019;8(22):e014367.
Wood D. Staged complete revascularization for coronary artery disease vs medical management alone in patients with as undergoing transcatheter aortic valve replacement (COMPLETE TAVR). Identifier: NCT04634240; April 8, 2022. ClinicalTrials.gov